Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system

Published:2023-07-31 Issue: Volume: Page:1-8
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Li Zhiping¹,Zou Wenbin²,Yuan Jiao¹,Zhong Yunxiang¹,Fu Zhiwen³

Affiliation:

1. Department of Pharmacy, Dongguan Binhaiwan Center Hospital, Dongguan, China

2. Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

3. Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2243220

Reference31 articles.

1. Cancer statistics, 2023

2. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer in the US

3. Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review

4. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going

5. EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events associated with fluorouracil use in patients with metastatic colorectal cancer: a real-world pharmacovigilance study based on the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-07-23

2. Comparing the adverse effects of ketamine and esketamine between genders using FAERS data;Frontiers in Pharmacology;2024-07-12

3. An observational study on the safety of teprotumumab based on FAERS database;Endocrine;2024-05-17

4. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database;Frontiers in Pharmacology;2024-02-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3